National Advisory Council for Environmental Policy and Technology (NACEPT)
Endocrine Disruptor Methods Validation Subcommittee (EDMVS)
Meeting by Conference Call
June 11, 2002
10:00 AM - 12:00 noon EDT
Provide comments and advice on the Steroidogenesis DRP (Tier I).
10:00 - 10:05 Phoning in
10:05 - 10:10 Roll Call
10:10 - 10:40 Steroidogenesis DRP (Tier I) Jerry Goldman, NHEERL, ORD, EPA
10:40 - 11:40 Discussion on Steroidogenesis DRP
1. Does the EDMVS agree with the recommendation of the DRP that EPA should commence prevalidation studies on the sectioned testis assay for steroidogenesis?
2. If yes to #1: Approximately 250 mg or 1/4 of an adult SD rat testis
is the sample size generally described by investigators. Should the
EPA conduct a study to investigate the sensitivity of the preparations
of testicular tissue less the 250 mg to determine an optimal and/or
threshold amount to use?
3. The DRP recommends that the test substances listed below be evaluated
during prevalidation. Does the EDMVS agree with the choice of test substances?
bisphenol A (inhibits steroidogenic signal transduction)
lindane (inhibits signal transduction and the StAR protein)
ketoconazole (a weak imidazole anti-fungal; inhibits P450scc and aromatase)
genistein ( a weak phytoestrogen/flavanoid; inhibits 3ß-HSD)
flutamide (inhibits P450c17)
econazole (a potent imidazole; inhibits aromatase)
aminoglutethimide (positive control; inhibits P450scc)
finasteride (negative control; inhibits 5a-hydroxylase)
4. Should EPA investigate the use of MA-10, R2C and H295R cell lines as alternatives to the sectioned testis assay in the EDSP? If so, which cell line?
11:40 - 11:55 Public Comment
Members of the public will be given an opportunity to comment and are requested to focus their comments on issues related to the Steroidogenesis DRP to the extent possible. The amount of time given to each individual will depend on the number of people wishing to provide comment.
11:55 - 12:00 Next Steps and Agenda for July 23-24, 2002 Meeting